WO2023187713 - METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING LIVER DISEASES
National phase entry is expected:
Publication Number
WO/2023/187713
Publication Date
05.10.2023
International Application No.
PCT/IB2023/053195
International Filing Date
30.03.2023
Title **
[English]
METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING LIVER DISEASES
[French]
MÉTHODES ET COMPOSITIONS POUR PRÉDIRE ET TRAITER DES MALADIES HÉPATIQUES
Applicants **
CBSBIOSCIENCE CO., LTD.
THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors
PARK, Jin Young
YU, Yunsuk
KIM, Chang Min
BAE, Si Hyun
SUNG, Pil Soo
Priority Data
63/362,187
30.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3061 | |
| EPO | Filing, Examination, Granting | 22852 | |
| Japan | Filing, Examination, Granting | 2773 | |
| South Korea | Filing, Examination, Granting | 2387 | |
| USA | Filing, Examination, Granting | 9940 |
Total:
41,013
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Biomarkers that can be used for the detection or diagnosis of disease states, preferably liver fibrosis, NAFLD, NASH, and/or cirrhosis, to the prediction of disease prognosis and/or a treatment outcome, to the identification of a treatment regimen for liver fibrosis, NAFLD, NASH, and/or cirrhosis, and/or to indicate the responsiveness to the treatment regimen for liver fibrosis, NAFLD, NASH, and/or cirrhosis in a subject are described. Also described are probes capable of detecting the biomarkers and related methods and kits for determining liver fibrosis, NAFLD, NASH, and/or cirrhosis disease states and/or identification of treatment regimens for the liver fibrosis, NAFLD, NASH, and/or cirrhosis disease states.[French]
Des biomarqueurs qui peuvent être utilisés pour la détection ou le diagnostic d'états pathologiques, de préférence la fibrose hépatique, la NAFLD, la NASH et/ou la cirrhose, la prédiction d'un pronostic de maladie et/ou d'un résultat de traitement, l'identification d'un régime de traitement pour la fibrose hépatique, la NAFLD, la NASH et/ou la cirrhose, et/ou pour indiquer la réactivité au régime de traitement pour la fibrose hépatique, la NAFLD, la NASH et/ou la cirrhose chez un sujet. L'invention concerne également des sondes capables de détecter les biomarqueurs et des méthodes ainsi que des kits associés pour déterminer des états pathologiques de la fibrose hépatique, de la NAFLD, de la NASH et/ou de la cirrhose et/ou l'identification de régimes de traitement pour la fibrose hépatique, la NAFLD, la NASH et/ou des états pathologiques de la cirrhose.